Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119066 · ClinicalTrials.gov registry record · Phase 2
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 422
- Enrollment target
NCT01119066: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01119066 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 422 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01119066, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 422 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD). Some studies have been done with CliniMACS, but the Food and Drug Administration (FDA) has not yet approved it.
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Busulfan
- DRUG Thiotepa
- RADIATION total body irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2010-05-03 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119066
The ClinicalTrials.gov registry entry for NCT01119066 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01119066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119066 about?
NCT01119066 is a clinical study titled "HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies". The purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD). Some studies have been done with CliniMACS, but the Food and Drug Administration (FDA)...
What is the current status of trial NCT01119066?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 422 participants. The study started on 2010-05-03. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT01119066?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Busulfan (DRUG), Thiotepa (DRUG), total body irradiation (RADIATION).
Who is sponsoring clinical trial NCT01119066?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.